tbuckley/cabot-search huggingface dataset:
OA03.06 Overall Survival and Forced Vital Capacity in the LUME-Meso Study of Nintedanib + Pemetrexed/Cisplatin in Patients with Mesothelioma
Authors: S. Novello, A. Nowak, F. Grosso, N. Steele, S. Popat, L. Greillier, T. John, N. Leighl, M. Reck, N. Pavlakis, J.B. Sorensen, D. Planchard, G.L. Ceresoli, B. Hughes, J. Mazieres, M. Socinski, U. Von Wangenheim, J. Barrueco, N. Morsli, G. Scagliotti
Journal: Journal of Thoracic Oncology (2017)
Abstract 13214: Right Ventricular-Vascular Coupling in Acute Hemodynamic Stress: A Simple Method of Estimation and Relationship With Right Ventricular Ejection Fraction and Afterload
Authors: Muddassir Mehmood, Robert W Biederman, Mary C McCarthy, Kathryn M Tchorz
Journal: Circulation (2015)

Objectives: Gold standard of right ventricular (RV) function is ratio of end-systolic to arterial elastance from synchronized volume and pressure measurements. Quantification of ventricular-vascular coupling (VVc) using non-simultaneous common right heart catheterization and cardiac imaging has been described. Hypothesis: VVc estimated from simultaneous pressure and volume measurements using Swan-Ganz TM (Edwards Lifesciences, Irvine, CA) advanced technology catheters would be feasible and clinically relevant. Methods: 32 mechanically ventilated adult critically ill trauma/general surgery patients were enrolled within 6 hours of admission. Hemodynamics were transduced every 12 hours for 48 hours. VVc was quantified as ratio of pulmonary artery (PA) effective elastance (E a ) to RV maximal end-systolic elastance (E max ). Mean PA pressure (mPAP) was used as surrogate of RV end-systolic pressure. Right ventricular end-systolic volume index (ESVI) was calculated as difference of end-diastolic volume index and stroke volume index (SVI). E(a) was calculated as (mPAP - PCWP)/SVI and E(max) as mPAP/ESVI. Results: Serial E a /E max inversely correlated with RV ejection fraction (RVEF) (r = -0.89, p &lt;0.001; r = -0.57, p = 0.001; r = -0.73, p &lt;0.001; r = -0.38, p =0.052, and r -0.55, p &lt;0.03) (Figure 1) and pulmonary arterial capacitance (PAC) (r = -0.59, -0.64, -0.49, -0.53, and -0.41, p ≤ 0.03). Pulmonary vascular resistance (PVR) correlated with E a /E max (r = 0.66, 0.61, 0.68, 0.66, 0.52, p ≤ 0.004). Non-survivors (n = 7) had higher E a /E max (indicating uncoupling) at 48 hours (2.3 ± 1.8 vs. 1.4 ± 1.8, p = 0.036). AUC for Ea/Emax at 48 hours and mortality was comparable to RVEF. Conclusions: In mechanically ventilated critically ill and/or injured adults, estimation of VVc using advanced technology pulmonary artery catheter is feasible. E a /E max is related to PVR and inversely related to RVEF and PAC. Estimation of E a /E max may assist in optimization of resuscitation.
Potential use for sulfasalazine in lung cancer therapy
Authors: Peter W. Gout, Jun Guan, Yuwei Wang, Hui Xue, Dan W. Doxsee, Margaret Sutcliffe, J. C. Cutz, Jean Leriche, Gwyn Bebb, Stephen Lam, Y. Z. Wang
Journal: Cancer Research (2004)

3844  The amino acid, cystine, or its reduced form, cysteine, is essential for cell growth and metabolism. While cyst(e)ine is nutritionally a non-essential amino acid, certain tissues cannot synthesize it, rendering their growth critically dependent on uptake of cyst(e)ine from their micro-environment. Sulfasalazine (SASP), a drug used for treatment of rheumatoid arthritis and Crohn’s disease, was previously shown to inhibit the xc- cystine/glutamate antiporter, a common plasma membrane cystine transporter. At patient-tolerated levels (about 0.2 mM), SASP can inhibit both xc--mediated cellular uptake of cystine and supply of cysteine by somatic cells, an xc--mediated process; intraperitoneal administration of SASP to rats markedly inhibited growth of lymphoma transplants (Gout et al., Anti-Cancer Drugs 14:21, 2003). In the present study we investigated the growth dependencies on extracellular cystine of a variety of cultured human lung cancer cell lines, including the H460 (large cell carcinoma), H226 (squamous cell carcinoma) and H82 (small cell lung cancer (SCLC)). The cells were tested by culturing them in RPMI-1640 medium supplemented with dialyzed fetal bovine serum (10%) and antibiotics, in the absence and presence of cystine. Tumor growth-inhibitory activity of SASP was examined using SCID-Rag2M mice carrying growing SCLC tissue xenografts (from a patient designated AB79) grafted under the renal capsules; notably, these xenografts were markedly resistant to a 7-day conventional treatment with cisplatin and etoposide, as shown by continuing, but reduced growth. In vitro it was found that the growth of the H460 large cell carcinoma cell line in the absence of cystine was about 5% of that of the control, increasing to approximately 50% when cystathionine (0.15 mM), an immediate precursor of cysteine, was added. This indicates that these cells contained gamma-cystathionase for production of cysteine via cleavage of cystathionine. Similar results were obtained with the H226 squamous cell carcinoma and H82 SCLC cells. In vivo, intraperitoneal administration of SASP at 250 mg/kg b.i.d. for 7 days markedly inhibited growth of the AB79 xenografts relative to controls, i.e. by 51% (p
Epidemie da Norovirus trasmesse da alimenti associate con il consumo di ostriche dell'Etang de Thau, Francia, dicembre 2002
Authors: A Doyle, D Barataud, A Gallay, J M Thiolet, S Le Guyaguer, E Kohli, V Vaillant
Journal: Eurosurveillance (2004)

Nel gennaio 2003, l'Institut de Veille Sanitaire ricevette notifica di cluster di gastroenterite (GE) ritenute essere associate con il consumo di ostiche allevate nell'Etang de Thau, nel sud della Francia. Nello stesso periodo fu riportata un'epidemia (200+ casi) in Italia associata con ostriche dell'Etang de Thau. Fu condotta un'indagine per determinare la fonte e il veicolo delle epidemie. 
Furono condotte una analisi descrittiva dei cluster riportati in Francia, un'analisi microbiologica dei campioni fecali e delle ostriche, la tipizzazione dei norovirus e un'indagine ambientale nell'Etang de Thau. Fu anche condotto uno studio di coorte retrospettivo tra coloro che avevano partecipato ad alcuni pasti in famiglia a Parigi.
Si poterono attribuire tredici cluster familiari in quattro distretti (69 casi) al consumo di ostriche di Thau basandosi sull'evidenza descrittiva. Le ostriche distribuite in un ufficio a Parigi e consumate durante 14 pasti di famiglia tra il 19 e il 24 dicembre portarono a un'ulteriore epidemia. In questa epidemia il tasso di attacco fu 21/36 (58%) per i consumatori di ostriche di Thau e di 0/22 per i non-consumatori (p=0,00002). Furono trovati norovirus (genotipo I e II) nei campioni fecali da 4 cluster e in ostriche da 3 cluster (compresa Parigi). Indagini ambientali rivelarono forti piogge, l'inondazione di una stazione di depurazione dell'acqua e contaminazione fecale dell'Etang de Thau a dicembre.
Le ostriche dell'Etang de Thau furono responsabili di un certo numero di cluster di GE da norovirus nell'inverno 2002 in Francia e anche in Italia. Alti livelli di Escherichia Coli nelle acque del Thau e nei molluschi portarono a una richiesta officiale, a meta-dicembre, di depurazione delle ostriche prima della distribuzione. Questo non fu possibile, per mancanza di sistemi di depurazione. Questa indagine ha contribuito a un cambiamento nel modo in cui le aree di coltura dei molluschi sono classificate in Francia.
Checkmate 743: A phase 3, randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma.
Authors: Gerard Zalcman, Solange Peters, Aaron Scott Mansfield, Thierry Marie Jahan, Sanjay Popat, Arnaud Scherpereel, Wenhua Hu, Giovanni Selvaggi, Paul Baas
Journal: Journal of Clinical Oncology (2017)

TPS8581 Background: Malignant pleural mesothelioma (MPM) is an aggressive cancer with a 5-year overall survival (OS) rate of &lt; 10%. At diagnosis, most patients (pts) have unresectable disease. Combination chemotherapy of cisplatin (or carboplatin as an alternative) + pemetrexed is the approved first-line standard of care. Phase 1 and 2 data suggest that targeting immune checkpoint pathways (eg, programmed death [PD]-1/PD-ligand 1 [PD-L1] and/or cytotoxic T-lymphocyte antigen-4 [CTLA-4]) may provide benefit with acceptable safety in MPM. In pts with previously treated, malignant mesothelioma, single-agent tremelimumab (a CTLA-4 inhibitor antibody) was active but did not improve OS vs placebo. In a phase 2 study of nivo (a fully human PD-1 immune checkpoint inhibitor antibody) in 34 pts with MPM that progressed after first-line platinum-based chemotherapy, 12-week disease control rate (DCR) was 50%, 5 pts had partial response, and 12 pts had stable disease. Given the data with single-agent CTLA-4 and PD-1 inhibitors and that CTLA-4 inhibition can induce PD-L1 expression, there is reason to anticipate synergy when combining CTLA-4 and PD-1 inhibitors in MPM. A phase 2 study assessing nivo alone and nivo + ipi (a CTLA-4 inhibitor antibody) in MPM is ongoing. CheckMate 743 (NCT02899299) is a phase 3 study that will evaluate the efficacy and safety of first-line nivo + ipi vs chemotherapy for MPM. Methods: Approximately 600 adult pts with unresectable MPM and ECOG performance status 0–1 will be randomized. Pts are ineligible if they have primary peritoneal, pericardial, or tunica vaginalis testis mesotheliomas; have active, untreated CNS metastases; or had received prior systemic therapy for pleural mesothelioma or a prior PD-1/PD-L1 or CTLA-4 checkpoint inhibitor antibody. Pts are randomized 1:1 to receive nivo + ipi or pemetrexed + cisplatin/carboplatin. Primary endpoints are OS and progression-free survival (PFS), assessed by blinded independent central review. Secondary endpoints are objective response rate (ORR), DCR, and correlation of PD-L1 expression level and efficacy (ORR, PFS, and OS). Clinical trial information: NCT02899299.
Cognitive behavioural therapy halves the risk of repeated suicide attempts: systematic review
Authors: Peter C Gøtzsche, Pernille K Gøtzsche
Journal: Journal of the Royal Society of Medicine (2017)

Objective To study whether cognitive behavioural therapy decreases suicide attempts in people with previous suicide attempts. Design Systematic review and meta-analysis. Setting Randomised trials that compare cognitive behavioural therapy with treatment as usual. Participants Patients who had engaged in any type of suicide attempt in the six months prior to trial entry resulting in presentation to clinical services. Main outcome measure Suicide attempt. Results We included ten trials, eight from Cochrane reviews and two from our updated searches (1241 patients, 219 of whom had at least one new suicide attempt). Cognitive behavioural therapy compared to treatment as usual reduced the risk of a new suicide attempt; risk ratio 0.47; 95% confidence interval 0.30-0.73; p = 0.0009; I2 = 57%. Only seven suicides were reported (3 versus 4). One trial had an unusually large effect; if this trial is excluded, the risk ratio becomes 0.61 (0.46-0.80) and the heterogeneity in the results disappears (I2 = 0%). Conclusions Cognitive behavioural therapy reduces not only repeated self-harm but also repeated suicide attempts. It should be the preferred treatment for all patients with depression.
Obesity and gynaecological and obstetric conditions: umbrella review of the literature
Authors: Ilkka Kalliala, Georgios Markozannes, Marc J Gunter, Evangelos Paraskevaidis, Hani Gabra, Anita Mitra, Vasso Terzidou, Phillip Bennett, Pierre Martin-Hirsch, Konstantinos K Tsilidis, Maria Kyrgiou
Journal: BMJ (2017)

<b>Objective</b>&nbsp;To study the strength and validity of associations between adiposity and risk of any type of obstetric or gynaecological conditions. <b>Design</b>&nbsp;An umbrella review of meta-analyses. <b>Data sources</b>&nbsp;PubMed, Cochrane database of systematic reviews, manual screening of references for systematic reviews or meta-analyses of observational and interventional studies evaluating the association between adiposity and risk of any obstetrical or gynaecological outcome. <b>Main outcomes</b>&nbsp;Meta-analyses of cohort studies on associations between indices of adiposity and obstetric and gynaecological outcomes. <b>Data synthesis</b>&nbsp;Evidence from observational studies was graded into strong, highly suggestive, suggestive, or weak based on the significance of the random effects summary estimate and the largest study in the included meta-analysis, the number of cases, heterogeneity between studies, 95% prediction intervals, small study effects, excess significance bias, and sensitivity analysis with credibility ceilings. Interventional meta-analyses were assessed separately. <b>Results</b>&nbsp;156 meta-analyses of observational studies were included, investigating associations between adiposity and risk of 84 obstetric or gynaecological outcomes. Of the 144 meta-analyses that included cohort studies, only 11 (8%) had strong evidence for eight outcomes: adiposity was associated with a higher risk of endometrial cancer, ovarian cancer, antenatal depression, total and emergency caesarean section, pre-eclampsia, fetal macrosomia, and low Apgar score. The summary effect estimates ranged from 1.21 (95% confidence interval 1.13 to 1.29) for an association between a 0.1 unit increase in waist to hip ratio and risk endometrial cancer up to 4.14 (3.61 to 4.75) for risk of pre-eclampsia for BMI &gt;35 compared with &lt;25. Only three out of these eight outcomes were also assessed in meta-analyses of trials evaluating weight loss interventions. These interventions significantly reduced the risk of caesarean section and pre-eclampsia, whereas there was no evidence of association with fetal macrosomia. <b>Conclusions</b>&nbsp;Although the associations between adiposity and obstetric and gynaecological outcomes have been extensively studied, only a minority were considered strong and without hints of bias.
TCT-79 What Biomarker Threshold for Periprocedural Myocardial Infarction Following PCI and CABG in Left Main Disease is Prognostically Relevant? Analysis from the EXCEL Trial
Authors: Shmuel Chen, Ori Ben-Yehuda, Thomas McAndrew, Ioanna Kosmidou, Bjorn Redfors, Marie-Claude Morice, David Kandzari, Adrian Banning, Ovidiu Dressler, Martin Leon, A. Pieter Kappetein, Joseph Sabik, Patrick Serruys, Gregg Stone
Journal: Journal of the American College of Cardiology (2017)
Remarkable response to cetuximab-containing chemotherapy for tongue cancer refractory to immune checkpoint inhibitors
Authors: Hirotaka Suto, Naomi Kiyota, Yoshinori Imamura, Yasuko Hyogo, Kei Takenaka, Yoshiaki Nagatani, Meiko Nishimura, Masanori Toyoda, Toru Mukohara, Hironobu Minami
Journal: Annals of Oncology (2017)
Mid- and Long-Term Outcome Comparisons of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents
Authors: Xin-Lin Zhang, Qing-Qing Zhu, Li-Na Kang, Xue-Ling Li, Biao Xu
Journal: Annals of Internal Medicine (2017)

Background: Percutaneous coronary interventions to implant bioresorbable vascular scaffolds (BVSs) were designed to reduce the late thrombotic events that occur with metallic stents. Purpose: To estimate the incidence of scaffold thrombosis after BVS implantation and compare everolimus-eluting BVSs with everolimus-eluting metallic stents (EESs) in terms of safety and efficacy at mid- and long-term follow-up in adults who had a percutaneous coronary intervention. Data Sources: PubMed, EMBASE, the Cochrane Library, conference proceedings, and relevant Web sites from inception until 20 May 2017, without language restriction. Study Selection: 7 randomized trials and 38 observational studies (each with a minimum of 6 months and 100 patient-years of follow-up) in adults with coronary artery disease who had a BVS or an EES and reported scaffold or stent thrombosis (main outcome) or other secondary outcomes (such as death, myocardial infarction, or revascularization). Data Extraction: 2 reviewers independently extracted study data, rated study quality, and assessed strength of evidence. Data Synthesis: The pooled incidence of definite or probable scaffold thrombosis after BVS implantation was 1.8% (95% CI, 1.5% to 2.2%) at a median follow-up of 1 year (41 studies, 21 884 patients) and 0.8% (CI, 0.5% to 1.3%) beyond 1 year (14 studies, 4688 patients). Seven trials involving 5578 patients that directly compared BVSs with EESs showed an increased risk for definite or probable scaffold thrombosis (odds ratio [OR], 3.40 [CI, 2.01 to 5.76]) with BVSs at a median follow-up of 25 months. Increased risks were present at early (prominently subacute), late, and very late stages, and odds beyond 1 year were almost double those seen within 1 year. Bioresorbably vascular scaffolds increased risks for myocardial infarction (OR, 1.63 [CI, 1.26 to 2.10]), target lesion revascularization (OR, 1.31 [CI, 1.03 to 1.67]), and target lesion failure (OR, 1.37 [CI, 1.12 to 1.66]); the odds for these 3 end points also increased over time. The incidences of all-cause, cardiac, and noncardiac death and of target vessel and any revascularization did not differ. Limitation: Quality of observational studies was unclear, and some data were unpublished. Conclusion: Compared with EESs, BVSs increased the risks for scaffold thrombosis and other thrombotic events at mid- and long-term follow-up, and risks increased over time. Primary Funding Source: National Natural Science Foundation of China.
TCT-398 Associations Between Atrial Fibrillation and Clinical Outcomes Among Patients Undergoing Transcatheter Aortic Valve Replacement With Self-Expanding Devices: Results From the United States STS/ACC TVT Registry
Authors: Jaya Chandrasekhar, Birgit Vogel, Usman Baber, Susheel Kodali, Paul Sorajja, Wilson Y. Szeto, Michael J. Reardon, Jeffrey J. Popma, Roxana Mehran, George Dangas
Journal: Journal of the American College of Cardiology (2017)
TCT-563 Prospective, controlled, clinical randomized trial evaluating novel, microcrystalline and biodegradable polymer paclitaxel coated balloon for the treatment of femoro-popliteal disease (The BIOPAC trial) - one year outcome
Authors: Piotr Buszman, Przemek Nowakowski, Krzysztof Milewski, Bartlomiej Orlik, Aleksander Zurakowski, Tomasz Ludyga, Marcin Debinski, Mateusz Kachel, Anna Turek, Juan Granada, R. Stefan Kiesz, Paweł Buszman
Journal: Journal of the American College of Cardiology (2017)
Low interim influenza vaccine effectiveness, Australia, 1 May to 24 September 2017
Authors: Sheena G Sullivan, Monique B Chilver, Kylie S Carville, Yi-Mo Deng, Kristina A Grant, Geoff Higgins, Naomi Komadina, Vivian KY Leung, Cara A Minney-Smith, Don Teng, Thomas Tran, Nigel Stocks, James E Fielding
Journal: Eurosurveillance (2017)

In 2017, influenza seasonal activity was high in the southern hemisphere. We present interim influenza vaccine effectiveness (VE) estimates from Australia. Adjusted VE was low overall at 33% (95% confidence interval (CI): 17 to 46), 50% (95% CI: 8 to 74) for A(H1)pdm09, 10% (95% CI: -16 to 31) for A(H3) and 57% (95% CI: 41 to 69) for influenza B. For A(H3), VE was poorer for those vaccinated in the current and prior seasons.
TCT-174 Implementation of computational fluid dynamics increases the diagnostic performance of angiography-derived indices of stenosis severity
Authors: Hernan Mejia-Renteria, Francesco Lauri, Joo Myung Lee, Nina van der Hoeven, Guus de Waard, Alfonso de Hoyos, Fernando Macaya, Nicola Ryan, Nieves Gonzalo, Pilar Jimenez-Quevedo, Luis Nombela Franco, Ivan Nuñez-Gil, Pablo Salinas, Maria Del Trigo, Maria Perez-Vizcayno, Antonio Fernandez-Ortiz, Carlos Macaya, Bon-Kwon Koo, Niels van Royen, Javier Escaned
Journal: Journal of the American College of Cardiology (2017)
TCT-242 Cost Savings Associated with Next-day Discharge among US Medicare Beneficiaries Undergoing Transcatheter Aortic Valve Replacement
Authors: Sandra Lauck, David Cohen, Suzanne Baron, Matthew Reynolds, Seth Clancy, Philippe Genereux, Vinod Thourani, Susheel Kodali, John Webb, David Wood
Journal: Journal of the American College of Cardiology (2017)
Abstract 17781: Surgical Revascularization in Acute Coronary Syndromes: Minimally Invasive Hybrid Strategy versus Conventional Coronary Artery Bypass Grafting
Authors: Ralf E Harskamp, Henry A Liberman, Rajendra H Mehta, Wissam Jaber, Thomas A Vassiliades, Habib Samady, Michael E Halkos
Journal: Circulation (2015)

Background: Hybrid coronary revascularization (HCR), which combines minimally invasive bypass surgery and percutaneous coronary intervention of non-LAD vessels, constitute a less invasive alternative to conventional coronary artery bypass grafting (CABG). The safety and effectiveness of HCR in acute coronary syndromes (ACS) as a surgical coronary revacularization strategy is unknown. Methods: Patients presenting with ACS who underwent HCR at a U.S. academic center (1/2008-9/2013) were included. These patients were matched 1:4 to similar individuals who underwent CABG using a propensity-score matching algorithm. Conditional logistic regression and Cox regression stratified on matched pairs were performed to evaluate the association of HCR versus CABG on the outcomes of 30-day MACCE (a composite of mortality, myocardial infarction (MI) and stroke), peri-procedural complications, and 3-year mortality. Results: Of 585 patients (HCR=117, CABG=468) in the propensity-score matched cohort, the 30-day MACCE was comparable after HCR and CABG (4.3% vs. 3.6%, odds ratio: 1.19, 95%-CI:0.43-3.19, p=0.75). Compared with CABG, HCR resulted in fewer procedural complications (7.7% vs. 16.0%, p=0.037), fewer blood transfusions (0 95%-CI:0-0 vs 1 95%-CI:0-2, p&lt;0.001), lower chest-tube drainage (760cc 95%-CI:555-1090 vs. 890cc 95%-CI:660-1130, p&lt;0.001) and shorter length-of-stay (4, 95%-CI:3-5 versus 5, 95%-CI:4-7 days, p&lt;0.001). Over a 3-year follow-up period, mortality was similar after HCR and CABG (6.0% vs. 7.0%, hazard ratio: 0.92, 95%-CI:0.33-2.54, p=0.87). Conclusion: In this exploratory analysis we found that among patients with ACS the use of HCR appeared safe, with fewer procedural complications, less blood product use, and faster recovery with similar longitudinal outcomes relative to conventional CABG surgery. Future multi-center studies involving a large number of patients with ACS are needed to confirm these findings.
Disagreement of diameter and volume measurements for pulmonary nodule size estimation in CT lung cancer screening
Authors: Marjolein A Heuvelmans, Joan E Walter, Rozemarijn Vliegenthart, Peter M A van Ooijen, Geertruida H De Bock, Harry J de Koning, Matthijs Oudkerk
Journal: Thorax (2017)

We studied 2240 indeterminate solid nodules (volume 50–500mm 3 ) to determine the correlation of diameter and semi-automated volume measurements for pulmonary nodule size estimation. Intra-nodular diameter variation, defined as maximum minus minimum diameter through the nodule’s center, varied by 2.8 mm (median, IQR:2.2–3.7 mm), so above the 1.5 mm cutoff for nodule growth used in Lung CT Screening Reporting and Data System (Lung-RADS). Using mean or maximum axial diameter to assess nodule volume led to a substantial mean overestimation of nodule volume of 47.2% and 85.1%, respectively, compared to semi-automated volume. Thus, size of indeterminate nodules is poorly represented by diameter. Trial registration number Pre-results, ISRCTN63545820 .